Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Anika Therapeutics, Inc.ANIK · Entity 6005 | Chief Operations Officer | January 27, 2017 | January 31, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Anika Therapeutics, Inc.
Report date January 27, 2017 · Filed January 31, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.13 · Expires 2027-01-27 | Direct | 16,875 |
Reported balance
After 2017-01-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-01-27 · Grant · Acquired 16,875 · Balance 16,875 F1: The stock options vest in three equal annual installments beginning January 27, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options vest in three equal annual installments beginning January 27, 2018.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 27, 2017 Filed Jan 31, 2017 21:06 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantStock Option (Right to Buy) · Derivative | 16,875 | $0.00 Strike: $50.13 | $0.00 |
DisclosureSEC source: 0001171843-17-000584 · formfour.xml · derivative · entry 1 Alexander Dana M. · CIK 0001670884 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,875 Underlying: Common Stock · 16,875 shares Expires 2027-01-27 F1 · derivative.exercise_date: The stock options vest in three equal annual installments beginning January 27, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.